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Interactions of mineralocorticoids and glucocorticoids in epi- Na1 retention) in large part because of the actions of
thelial target tissues. the enzyme 11b-hydroxysteroid dehydrogenase isoform
Background. In Na1-transporting epithelial target tissues,
2 (11b-HSD2). In the distal nephron, this enzyme func-such as mammalian kidney and the isolated toad bladder, gluco-
tions as a unidirectional dehydrogenase [6] metabolizingcorticoids (GCs) do not normally elicit Na1 retention. In mam-
malian kidney, however, they do cause kaliuresis. The presence endogenous GCs to their biologically inactive 11-dehy-
of 11b-hydroxysteroid dehydrogenase isoform 2 (11b-HSD2) dro derivatives (for example, cortisol to cortisone in hu-
in these target tissues inactivates the GCs, preventing them
mans and corticosterone to 11-dehydrocorticosterone infrom accessing mineralocorticoid receptors (MRs) and stimu-
rats). The 11-dehydro products of cortisol and corticoste-lating Na1 transport.
Results. The usually observed Na1 retention elicited by the rone are generally considered to be biologically inert
mineralocorticoid aldosterone was blunted when the GC corti- and have little or no affinity for either steroid receptor
costerone was coadministered along with aldosterone. How-
[1]. Children with a syndrome of apparent mineralocorti-ever, when corticosterone was administered along with a 11b-
coid excess (AME) provide the clinical evidence in sup-HSD2 inhibitor, a strong Na1 transport was elicited by an MR-
mediated mechanism. 11-Dehydrocorticosterone also blunted port of the “guardian” role of a renal 11b-HSD2. All of
aldosterone-elicited Na1 transport in these target tissues. these children have homozygous mutations in the 11b-
Conclusions. 11b-HSD2 appears to play two important roles
HSD2 gene that result in diminished 11b-HSD2 activityin the epithelial target tissues, kidney and toad bladder. The
[7, 8]. Children with AME display increased Na1 reten-first is to protect GC access to MR, and the second involves
the product of the enzyme to regulate the magnitude of aldoste- tion, K1 wasting, marked hypertension, and severely im-
rone-induced Na1 retention. paired conversion of cortisol to cortisone [9].
Secretion of GCs and other adrenal steroid precursors
is in general significantly greater than that of the mineral-
ocorticoid steroids. Since these adrenal corticosteroids,
under certain physiologic conditions, can also cause min-
eralocorticoid-like Na1 retention, many investigators haveIn mineralocorticoid target tissues, such as the kidney
and the parotid gland, mineralocorticoid receptors (MRs) suggested the possibility of functional interactions between
appear to be protected from the physiological effects of GCs and mineralocorticoids in the regulation of sodium
circulating endogenous glucocorticoids (GCs) [1, 2]. The and fluid homeostasis. The concept that 11b-HSD2 is a
endogenous GCs corticosterone and cortisol and the “protective enzyme” preventing GCs from accessing MR
mineralocorticoid aldosterone demonstrate equal bind- and causing mineralocorticoid-like Na1 retention [1, 2]
ing affinities for MR in vitro [1, 3, 4]. Under normal cir- further supports the idea of functional interactions.
cumstances, GCs do not bind to MR in vivo even though The isoform 11b-HSD1 has a wide tissue distribution
the circulating levels of cortisol (in humans) and cortico- and is also present in several target tissues of GCs and
sterone (rat) are approximately 500 times greater than mineralocorticoids [10, 11]. Although 11b-HSD1 may
that of aldosterone [5]. Cortisol and corticosterone do function as both a dehydrogenase and as an oxoreductase,
not induce mineralocorticoid-like actions (particularly a in most tissues, this isoform functions largely as a reduc-
tase, activating 11-dehydro-derivatives back to their par-
ent GC hormones. Thus, 11b-HSD1 may also play a roleKey words: antinatriuresis, 11b-HSD2, epithelial cells, kaliuresis, so-
dium transport, aldosterone. in the interactions between GCs and mineralocorticoids
in the regulation of electrolyte and fluid homeostasis.Ó 2000 by the International Society of Nephrology
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Table 1. Effect of steroids on the urinary excretion of sodium andREGULATION OF MINERALOCORTICOID
potassium in the ADX male rat
Na1 RETENTION AND K1 SECRETION
Na1/creatinine K1/creatinineBY GLUCOCORTICOIDS
Condition mmol/g mmol/g
Physiological paradoxes in the action of
Control 530658 139614
mineralocorticoids and glucocorticoids Aldo 0.1 mg/rat 202618a 291624a
Aldo 1 50 mg corticosterone 209615a 288627aSeveral years ago, our laboratory demonstrated that
Aldo 1 100 mg corticosterone 341618a,b 211624
the administration of physiologic dosages of aldosterone Aldo 1 250 mg corticosterone 503643b 444620a,b
Aldo 1 50 mg 11-dehydro 217621a 207618a,bto adrenally intact male rats elicited only a kaliuretic
Aldo 1 100 mg 11-dehydro 388650a,b 256615aeffect [12]. However, administration of the same dosage
Aldo 1 250 mg 11-dehydro 473630b 333637a
of aldosterone to adrenalectomized (ADX) male rats Corticosterone 50 mg 470663 226620a
Corticosterone 100 mg 536622 240616ainduced both antinatriuresis and kaliuresis, the effects
Corticosterone 250 mg 420619 345675acommonly associated with mineralocorticoids [12]. This
11-dehydro 50 mg 463631 109610
response pattern has also been reported in intact and 11-dehydro 100 mg 600622 143620
11-dehydro 250 mg 497675 441620aADX dogs [13]. These important observations are evi-
Mean 6 SE; N 5 6–8 animals per group.dence that secretory products from the adrenal gland
aP , 0.01 vs. controlregulate the renal sodium retention in response to aldo- bP , 0.01 vs. aldosterone alone
sterone.
Interestingly, a kaliuresis can be observed following
the administration of physiological dosages of either GC,
additional paradox in that inhibition of 11b-HSD2 in thecortisol, or corticosterone to ADX rats [14, 15]. This find-
kidney following treatment of ADX rats with either CBXing is paradoxical because the kaliuresis occurs following
or other 11b-HSD2 inhibitors allows GCs to access MRactivation of MRs without accompanying antinatriuresis.
with resulting antinatriuresis and enhanced kaliuresisThe separability of K1 from Na1 transport could be
[15]. One might have expected that access of corticoste-explained by the presence of MRs in two or more distinct
rone to MRs enhances the sodium-retaining actions ofpopulations of renal epithelial cells, each responding dif-
aldosterone rather than inhibiting them.ferently to the same stimulus or by a postreceptor modi-
fication resulting in different responses occurring in the
same cells. These experiments have not only provided
ROLE OF 11-DEHYDRO-DERIVATIVESadditional evidence that renal 11b-HSD2 does prevent
The above findings prompted us to look at the physio-GCs from causing excessive Na1 retention, but also sup-
logical role of the product of the enzyme 11b-HSD2, 11-ports the concept that separate mechanisms are responsi-
dehydrocorticosterone, in both the mammalian kidneyble for each of the physiological effects of mineralocorti-
and the isolated toad bladder. 11-Dehydrocorticosteronecoids, Na1 retention, and K1 secretion.
alone at physiological dosages is biologically inactive inWe have previously shown that corticosterone blunts
ADX rats, but when administered at higher dosages, itthe observed renal antinatriuretic response to aldosterone
does elicit a kaliuresis [21]. When 11-dehydrocorticoster-when both steroids are coadministered in physiologic doses
one is coadministered with aldosterone to an ADX rat,to ADX rats [16]. Similar findings that endogenous and
the renal antinatriuretic component of the physiologicalsynthetic GCs can inhibit the actions of aldosterone on
response to aldosterone was blunted in a dose-dependenturinary Na1 excretion have also been reported in hu-
fashion similar to that observed with corticosterone andmans [17] and in dogs [18]. Subsequent experiments by
aldosterone (Table 1). When given alone, neither corti-Brem et al using the isolated toad bladder preparation
costerone nor 11-dehydrocorticosterone at a dose of 250also demonstrated that corticosterone attenuated Na1
mg per rat had significant effects on urinary Na1 excre-transport elicited by aldosterone [19]. However, isolated
tion [21].toad bladders exposed to physiologic concentrations of
Corticosterone alone possessed intrinsic kaliuretic ac-corticosterone alone do not generate an increase in Na1
tivity at doses of 50, 100, and 250 mg per rat comparedtransport comparable to that caused by aldosterone,
with the control group. 11-Dehydrocorticosterone, how-most likely because of the presence of the guardian en-
ever, only exhibited intrinsic kaliuretic activity at thezyme 11b-HSD2 [19]. When 11b-HSD2 in the toad blad-
highest dosage used (250 mg per rat). Aldosterone (0.1der is inhibited by pretreatment with carbenoxolone
mg per rat) alone caused a typical kaliuresis, while the(CBX), corticosterone induces a rise in Na1 transport
effects of a combination of corticosterone and aldoste-similar to that observed with aldosterone [20]. Thus, it
rone on urinary K1 excretion appeared to be additive atwould appear that corticosterone or one of its derivatives
the highest dosage of corticosterone only. Similar effectsmay be one of the adrenal products regulating the sodium-
retaining effects of aldosterone. This presents us with an were seen with the administration of aldosterone plus
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increase in luciferase activity was observed as expected.
However, if these same cells were incubated with both
11-dehydrocorticosterone and aldosterone, the lucifer-
ase activity was almost completely blocked. The 11-dehy-
drocorticosterone alone produced little or no luciferase
activity. When COS-7 cells were transfected with human
GC receptors and incubated with dexamethasone, a large
degree of luciferase activity could again be seen. How-
ever, 11-dehydrocorticosterone had no effect on the lu-
ciferase response when cells were incubated with both
dexamethasone and 11-dehydrocorticosterone. Thus, the
otherwise biologically inert metabolic product of 11b-
HSD2, 11-dehydrocorticosterone, appears able to di-
rectly affect the aldosterone action at the receptor level.
Fig. 1. Effect of 11-dehydrocorticosterone (11b-HSD2; 10 mmol/L)
in the serosal bath on the short circuit current (SCC) generated by
aldosterone (10 nmol/L). The 11-dehydrocorticosterone was added to CONCLUSION
the serosal bath at –60 minutes, and aldosterone was added at 0 time.
Data are expressed as mean 6 SE (N 5 6 pairs of toad bladders). Based on our findings, it appears that 11b-HSD2
Symbols are: (j) aldosterone 1 11b-HSD2; (e) aldosterone; *P , serves two purposes. In addition to the “guardian” role
0.001; **P , 0.01. (This figure is reproduced from Am J Physiol 261:
of 11b-HSD2, in which the enzyme limits the access of873–879, 1999 with permission from the American Physiological So-
ciety.) glucocorticoids to MRs, the 11-dehydro-product of 11b-
HSD2 serves to regulate the magnitude of aldosterone-
induced Na1 retention. The fact that at this moment
some of these findings appear paradoxical should spur
11-dehydrocorticosterone. Thus, both the end product of on our efforts in this area. It is uncertain at this time
11b-HSD2, 11-dehydrocorticosterone, and its substrate, whether 11-dehydro-GCs, which do not bind well to MR
corticosterone, can modify the magnitude of the Na1- [1], act as competitive antagonists. However, earlier stud-
retaining activity of aldosterone in the kidney, which is ies with toad bladder had indicated that 11-dehydrocorti-
consistent with the view that the adrenal GCs modulate costerone lowered the binding of aldosterone in the nu-
mineralocorticoid action. clei of cells in this target tissue [23]. Heterodimers of
Similar experiments were then performed using the MR and glucocorticoid receptors have been suggested
isolated toad bladder preparation. 11-Dehydrocorticos- to play a role(s) in the magnitude of target tissue re-
terone did not cause any effect on Na1 transport, as sponses [24]. Similarly, our findings that 11b-HSD1 in-
demonstrated by the short-circuit current in this model. hibitors, such as the bile acid chenodeoxycholic acid, can
However, when bladders were pretreated with 11-dehy- also cause the GC corticosterone to elicit Na1 retention
drocorticosterone and then stimulated with physiological [25] present a third paradox. These results may not only
concentrations of aldosterone [19], the short circuit cur- suggest a role for 11b-HSD1 in Na1 transport, but also
rent elicited by aldosterone was significantly suppressed for interactions in these processes by the newly discov-
(Fig. 1). Interestingly, when bladders were exposed to ered bile acid receptors (BARs), which are also present
the enzyme end product 11-dehydrocorticosterone and in kidney [26].
then stimulated with corticosterone [22], the short-circuit
current was enhanced relative to that seen with cortico- ACKNOWLEDGMENTS
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